Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: Evaluation of brimonidine as a model

Advances in Therapy

Volumn 18, Issue 6, 2001, Pages 282-297

  Abelson, Mark B ^a   Netland, Peter A ^b   Chapin, Matthew J ^c  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c Ophthalmic Research Associates Inc   (United States)

Author keywords

Brimonidine; Glaucoma; Intraocular pressure; Ocular hypertension; Pharmacoeconomics

Indexed keywords

APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; CARTEOLOL; DICLOFENAMIDE; DIPIVEFRINE; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; METHAZOLAMIDE; METIPRANOLOL; PILOCARPINE; TIMOLOL; TIMOLOL MALEATE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT SATISFACTION; QUESTIONNAIRE; VISION;

ADULT; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GLAUCOMA; HUMANS; MALE; OCULAR HYPERTENSION; QUALITY OF LIFE; QUINOXALINES; UNITED STATES;

EID: 0035707739     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850198     Document Type: Article

References (20)

1. Pharmacological therapy for glaucoma: A review
2. Shorterm "escape" and longterm "drift". The dissipation effects of the beta adrenergic blocking agents
3. Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma
4. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans
5. A follow-up study on the intraocular pressure response of timolol eye drops
6. Economics and cost-effectiveness in evaluating the value of cardiovascular lipid-lowering therapies: An industry perspective
7. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-Year results in glaucoma subjects
8. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three results
9. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular hypertension: A randomized clinical trial
10. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial
11. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma
12. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension
13. Pharmacoeconomics
14. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore eye survey
15. Systemic effects of medications used to treat glaucoma
16. Acute effects of beta blockade and exercise on mood and anxiety
17. Cost analysis of glaucoma medications
18. The dorzolamide/timolol combination versus timolol plus pilocarpine: Patient preference and impact on quality of life
19. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma